This is a phase I, single center, randomized, double-blind and parallel group clinical trial.~The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous injections of MW032 and Xgeva® in healthy volunteers.~The secondary objective are to assess the Clinical safety and immunogenicity similarity of single and subcutaneous injections of MW032 and Xgeva® in healthy volunteers.~At the same time, preliminary evaluate the pharmacodynamic similarity between MW032 and Xgeva®.~Subjects would receive a single 120mg（1.7mL）of MW032 or Xgeva® through subcutaneous injection.
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of MW032 and Xgeva® in healthy adults.